Aclaris Therapeutics (ACRS) Total Current Liabilities (2014 - 2026)

Aclaris Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 27.22% year-over-year to $27.4 million in Q1 2026; TTM through Mar 2026 was $27.4 million, a 27.22% increase from a year earlier, with the FY2025 full-year figure at $28.6 million, down 9.34% from the prior year.
• Total Current Liabilities declined to $27.4 million in Q1 2026 per ACRS's latest filing, from $28.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $31.6 million in Q4 2024 and bottomed at $15.7 million in Q2 2024.
• The 5-year median for Total Current Liabilities is $21.9 million (2022), against an average of $23.0 million.
• Across the five-year window, Total Current Liabilities tumbled 31.31% in 2024 and surged 71.15% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $21.9 million in 2022, then jumped by 41.09% to $31.0 million in 2023, then rose by 2.08% to $31.6 million in 2024, then slipped by 9.34% to $28.6 million in 2025, then declined by 4.45% to $27.4 million in 2026.
• Per Business Quant, the three latest ACRS Total Current Liabilities figures stand at $27.4 million (Q1 2026), $28.6 million (Q4 2025), and $25.6 million (Q3 2025).